Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis

Sibel Yilmaz-Oner; Gulsen Ozen; Meryem Can; Pamir Atagunduz; Haner Direskeneli; Nevsun Inanc

doi:10.3899/jrheum.150478

Back

Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis

Journal article

Open access

Peer reviewed

Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis

Sibel Yilmaz-Oner, Gulsen Ozen, Meryem Can, Pamir Atagunduz, Haner Direskeneli and Nevsun Inanc

Journal of rheumatology, Vol.42(11), pp.2066-2070

11/2015

DOI: 10.3899/jrheum.150478

PMID: 26472417

Files and links (1)

url

https://doi.org/10.3899/jrheum.150478View

Published (Version of record) Open Access

Abstract

Remission is the primary aim in the treatment of patients with rheumatoid arthritis (RA). In this study, we aimed to evaluate biomarker profiles of patients in remission by different criteria and compare these profiles with controls. Serum levels of calprotectin, interleukin 6 (IL-6), type II collagen helical peptide, C-terminal crosslinking telopeptide of type I collagen generated by matrix metalloproteinases (ICTP), matrix metalloproteinase 3 (MMP-3), resistin, and leptin were measured by ELISA in 80 patients. The patients were in Disease Activity Score at 28 joints with erythrocyte sedimentation rate (DAS28-ESR) remission, and had these characteristics: female/male 54/26, mean age 51.4 ± 12.1 years, mean disease duration 11.4 ± 8.1 years, rheumatoid factor positivity 68.7% (n = 55), anticyclic citrullinated peptide positivity 60.7% (n = 48). These patients were also evaluated for the American College of Rheumatology/European League Against Rheumatism (Boolean) and Simple Disease Activity Index (SDAI) remissions. Additionally, 80 age-, sex-, and comorbidity-matched individuals without rheumatic diseases were included in the study as controls. At recruitment of 80 patients in DAS28 remission, 33 patients (41.2%) were found in Boolean remission and 39 patients (48.7%) were in SDAI remission. Serum MMP-3, ICTP, resistin, and IL-6 levels of the 80 patients in DAS28 remission were statistically significantly higher than the controls. Patients in Boolean and SDAI remissions had significantly higher serum ICTP, resistin, and IL-6 levels in comparison with the controls. The 3 commonly used remission criteria of RA are almost similar with regard to patients' biomarker levels. Biomarker profiles of patients may provide complementary information to clinical evaluation of remission and may help to determine the patients under the risk of progression.

Adult

Age Factors

Analysis of Variance

Antirheumatic Agents - therapeutic use

Arthritis, Rheumatoid - blood

Arthritis, Rheumatoid - drug therapy

Arthritis, Rheumatoid - physiopathology

Biomarkers - blood

Blood Sedimentation

C-Reactive Protein - metabolism

Case-Control Studies

Disease Progression

Female

Humans

Interleukin-6 - blood

Leptin - blood

Leukocyte L1 Antigen Complex - blood

Male

Matrix Metalloproteinase 3 - blood

Matrix Metalloproteinase 3 - metabolism

Middle Aged

Prognosis

Remission Induction

Retrospective Studies

Rheumatoid Factor - blood

Risk Assessment

Severity of Illness Index

Sex Factors

Statistics, Nonparametric

Treatment Outcome

Details

Title: Subtitle: Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis
Creators: Sibel Yilmaz-Oner
Gulsen Ozen
Meryem Can
Pamir Atagunduz
Haner Direskeneli
Nevsun Inanc
Resource Type: Journal article
Publication Details: Journal of rheumatology, Vol.42(11), pp.2066-2070
DOI: 10.3899/jrheum.150478
PMID: 26472417
ISSN: 0315-162X
eISSN: 1499-2752
Language: English
Date published: 11/2015
Academic Unit: Internal Medicine
Record Identifier: 9984702947002771

Metrics

11 Record Views

7 Times Cited - Web of Science